Liver enzymes and risk of all-cause mortality in general populations: A systematic review and meta-analysis

International Journal of Epidemiology

Volumn 43, Issue 1, 2014, Pages 187-201

  Kunutsor, Setor K ^a,b   Apekey, Tanefa A ^b   Seddoh, Dorothy ^c   Walley, John ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Maranatha University College   (Ghana)

Author keywords

Alkaline phosphatase; Aminotransferases; Gamma glutamyltransferase; Meta analysis; Mortality

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

DATA SET; DOSE-RESPONSE RELATIONSHIP; ENZYME ACTIVITY; IDENTIFICATION METHOD; LITERATURE REVIEW; META-ANALYSIS; MORTALITY; POPULATION STRUCTURE; RISK FACTOR;

ALCOHOL CONSUMPTION; ARTICLE; ATTRIBUTABLE RISK; BIBLIOGRAPHIC DATABASE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; DATA EXTRACTION; DIABETES MELLITUS; DOSE RESPONSE; FOLLOW UP; HUMAN; LIVER DISEASE; LIVER DYSFUNCTION; MASS SCREENING; META ANALYSIS; MORTALITY; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; BLOOD; CAUSE OF DEATH; HEALTH SURVEY;

ALKALINE PHOSPHATASE; CAUSE OF DEATH; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; MORTALITY; POPULATION SURVEILLANCE; TRANSAMINASES;

EID: 84896807924     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyt192     Document Type: Article

References (62)

1. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001;38:263-355.
2. Wroblewski F, Ladue JS. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc Soc Exp Biol Med 1956;91:569-71.
3. Wroblewski F, Ladue JS. Serum glutamic oxalacetic aminopherase (transaminase) in hepatitis. J Am Med Assoc 1956;160:1130-34.
4. Tonelli M, Curhan G, Pfeffer M et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 2009;120:178-92.
5. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009;32:741-50.
6. Kunutsor SK, Apekey TA, Walley J. Liver aminotransferases and risk of incident type 2 diabetes: a systematic review and meta-analysis. Am J Epidemiol 2013;178: 159-71.
7. Schneider AL, Lazo M, Ndumele CE et al. Liver enzymes, race, gender and diabetes risk: the Atherosclerosis Risk in Communities (ARIC) Study. Diabet Med 2013;8:926-33.
8. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007;27:2729-35.
9. Schindhelm RK, Dekker JM, Nijpels G et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007;191:391-96.
10. Kim HC, Kang DR, Nam CM et al. Elevated serum aminotransferase level as a predictor of intracerebral hemorrhage: Korea Medical Insurance Corporation Study. Stroke 2005;36:1642-47.
11. Wannamethee SG, Sattar N, Papcosta O, Lennon L, Whincup PH. Alkaline phosphatase, serum phosphate, and incident cardiovascular disease and total mortality in older men. Arterioscler Thromb Vasc Biol 2013;33: 1070-76.
12. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005;112:2130-37.
13. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004;328:983.
14. Mannan HR, Stevenson CE, Peeters A, McNeil JJ. A new set of risk equations for predicting long term risk of all-cause mortality using cardiovascular risk factors. Prev Med 2013;56:41-45.
15. Breitling LP, Claessen H, Drath C, Arndt V, Brenner H. Gamma-glutamyltransferase, general and cause-specific mortality in 19,000 construction workers followed over 20 years. J Hepatol 2011;55:594-601.
16. Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009;50:1403-11.
17. Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C. Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem 2007; 53:940-46.
18. Fraser A, Thinggaard M, Christensen K, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase (GGT) and all-cause mortality: results from a population-based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins. Liver Int 2009;29: 1494-99.
19. Le Couteur DG, Blyth FM, Creasey HM et al. The association of alanine transaminase with aging, frailty, and mortality. J Gerontol A Biol Sci Med Sci 2010; 65:712-17.
20. Ford I, Mooijaart SP, Lloyd S et al. The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. Int J Epidemiol 2011;40:1530-38.
21. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008;135:1935-44.
22. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008;19: 2193-203.
23. McLernon DJ, Dillon JF, Sullivan FM et al. The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI). PLoS One 2012;7:e50965.
24. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology. JAMA 2000;283: 2008-12.
25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6: e1000097.
26. Calori G, Lattuada G, Ragogna F et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011;54:145-52.
27. Filipowicz R, Greene T, Wei G et al. Associations of serum skeletal alkaline phosphatase with elevated C-reactive protein and mortality. Clin J Am Soc Nephrol 2013;8:26-32.
28. Fulks M, Stout RL, Dolan VF. Using liver enzymes as screening tests to predict mortality risk. J Insur Med 2008;40:191-203.
29. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
30. Chê ne G, Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 1996;144: 610-21.
31. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992;135:1301-09.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-8.
33. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized doseresponse data. Stata J 2006;6:40-57.
34. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60.
35. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
36. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-708.
37. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
38. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
39. Rothman K, Greenland S. Modern Epidemiology. 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 1998.
40. Elinav E, Ackerman Z, Maaravi Y, Ben-Dov IZ, Ein-Mor E, Stessman J. Low alanine aminotransferase activity in older people is associated with greater long-term mortality. J Am Geriatr Soc 2006;54:1719-24.
41. Hovinen SM, Pitkala KH, Tilvis RS, Strandberg TE. Alanine aminotransferase activity and mortality in older people. J Am Geriatr Soc 2010;58:1399-401.
42. Beddhu S, Baird B, Ma X, Cheung AK, Greene T. Serum alkaline phosphatase and mortality in hemodialysis patients. Clin Nephrol 2010;74:91-96.
43. Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD. Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: Pooling of three British Health Surveys. J Hepatol 2012;57:1083-89.
44. Lee DS, Evans JC, Robins SJ et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 200;27:127-33.
45. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009; 136:477-85.
46. Wannamethee G, Ebrahim S, Shaper AG. Gammaglutamyl-transferase-determinants and association with mortality from ischemic-heart-disease and all causes. Am J Epidemiol 1995;142:699-708.
47. Nakamura K, Okamura T, Kanda H et al. The value of combining serum alanine aminotransferase levels and body mass index to predict mortality and medical costs: a 10-year follow-up study of National Health Insurance in Shiga, Japan. J Epidemiol 2006;16:15-20.
48. Strasak AM, Kelleher CC, Klenk J et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults. Arterioscler Tthromb Vasc Biol 2008;28:1857-65.
49. Loomba R, Doycheva I, Bettencourt R et al. Serum g-glutamyltranspeptidase predicts all-cause, cardiovascular and liver mortality in older adults. J Clin Exp Hepatol 2012;1-8.
50. Koehler E, Sanna D, Hansen BE et al. Gamma glutamyltransferase and aminotransferase levels are independently associated with all-cause mortality in elderly: Results of a population-based study. 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, 2011; 369A.
51. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
52. World Health Organization. Global Health Observatory. Country statistics. http://www.who.int/gho/countries/en/.
53. European Commission. Eurostat: Causes of Death. http://epp.eurostat.ec.europa.eu/portal/page/portal/health/public_health/data_public_health/main_tables.
54. Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005;112:2078-80.
55. Franzini M, Corti A, Martinelli B et al. Gamma-glutamyltransferase activity in human atherosclerotic plaques - biochemical similarities with the circulating enzyme. Atherosclerosis 2009;202:119-27.
56. Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
57. Al-Hamoudi W, Ali S, Hegab B et al. Revising the upper limit of normal for levels of serum alanine aminotransferase in a Middle Eastern population with normal liver histology. Dig Dis Sci 2013;58:2369-75.
58. Lee JK, Shim JH, Lee HC et al. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 2010; 51:1577-83.
59. Lee TH, Kim WR, Benson JT, Therneau TM, Melton LJ. Serum aminotransferase activity and mortality risk in a United States community. Hepatology 2008;47:880-87.
60. Fisher AL. Of worms and women: sarcopenia and its role in disability and mortality. J Am Geriatr Soc 2004;52: 1185-90.
61. Lazo M, Selvin E, Clark JM. Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med 2008;148:348-52.
62. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010;340:c221.